Cure rates of different local treatments for cutaneous, non-genital warts in healthy people at 1–18 months*
| Comparisons | Number of RCTs (number of patients) | Weighted event rates | RBI (95% CI) | NNT (CI) |
|---|---|---|---|---|
| TSA or TLA v placebo | 6 (376) | 73% v 48% | 62% (24 to 113) | 5 (3 to 10) |
| ILS bleomycin v placebo | 1 (31) | 94% v 73% | 28% (−8 to 78) | Not significant |
| T5FU v placebo | 1 (128) | 45% v 13% | 263% (80 to 631) | 4 (3 to 6) |
| TDNCB v placebo | 2 (80) | 80% v 43% | 83% (24 to 169) | 3 (2 to 6) |
| RBR | NNH | |||
|---|---|---|---|---|
| *ILS = intralesional; RBR = relative benefit reduction; RCTs = randomised controlled trials; T5FU = topical 5-fluorouracil; TDNCB = topical dinitrochlorobenzene; TLA = topical lactic acid; TSA = topical salicylic acid. Other abbreviations defined in glossary; RBI, RBR, NNT, NNH and CI calculated from data in article using a random effects model. | ||||
| Cryotherapy v placebo or no treatement | 2 (69) | 29% v 34% | 12% (−195 to 74) | Not significant |
| ILS interferons v placebo | 3 (150) | 31% v 34% | 13% (−33 to 44) | Not significant |